– Grant funding will support Save our Sons Duchenne Foundation in developing a digital health app –
SYDNEY, Sept. 7, 2023 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that an Australian patient advocacy organization is one of the two recipients of the company’s 2023 STRIVE Awards. The program provides grants to non-profit patient advocacy organizations serving the Duchenne community. Save our Sons Duchenne Foundation (SOSDF), one of the recipients of the award, is based in Australia and plans to develop a digital health app to help young men living with Duchenne manage their medical care.
As patients with Duchenne transition into adulthood and live independently, they manage their own medical care. SOSDF plans to develop a digital health app to help young men living with Duchenne across Australia. The app will help users actively manage their health to be better prepared both physically and mentally, thereby reducing the burden of care on themselves, carers and the health system. SOSDF will work with University of Queensland to develop the app.
The other recipient of the 2023 STRIVE Award is Blue Angels. Based in Brazil, Blue Angels was founded in 2019 to promote an improvement in the quality of life of people with disabilities through high performance training in adapted sports. Their vision fosters social inclusion of people with disabilities through adapted sports activities. With the STRIVE grant, Blue Angels will expand its power soccer program, a type of soccer played by people who have any kind of motor limitation and use wheelchairs. The organization will hire professionals to assist with the program, increase the number of players and acquire additional equipment.
“The 2023 STRIVE grant recipients have demonstrated a strong commitment to their local Duchenne communities. We are excited by the additional support they will be able to provide patients and their families through this grant funding,” said Mary Frances Harmon, senior vice president, Corporate Relations, PTC Therapeutics. “As we near a decade of the STRIVE Awards program, we are proud to continue to provide organizations with support to expand their services for the Duchenne community.”
About the STRIVE Awards Program
PTC launched the Strategies to Realize Innovation, Vision, and Empowerment (STRIVE) Awards program in 2015 to support initiatives that benefit the Duchenne community by increasing awareness, diagnosis, and education, and fostering the development of future patient advocates. Each year, an independent panel of external experts with knowledge in rare diseases, patient advocacy and funding initiatives, judge the entries for innovation, vision, and empowerment. Forty-one projects supporting the Duchenne community have received STRIVE grants since the program’s inception. For further information about the program and the 2023 award recipients, please visit: www.ptcstriveawards.com.
About Duchenne Muscular Dystrophy
Primarily affecting males, Duchenne is a rare and fatal genetic disorder that results in progressive muscle weakness from early childhood and leads to premature death in the mid-20s due to heart and respiratory failure. It is a progressive muscle disorder caused by the lack of functional dystrophin protein. Dystrophin is critical to the structural stability of all muscles, including skeletal, diaphragm, and heart muscles. Patients with Duchenne can lose the ability to walk (loss of ambulation) as early as 10 years old, followed by loss of the use of their arms. Duchenne patients subsequently experience life-threatening lung complications, requiring the need for ventilation support, and heart complications in their late teens and 20s.
About PTC Therapeutics, Inc.
PTC is a global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC’s ability to innovate to identify new therapies and to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines. PTC’s mission is to provide access to best-in-class treatments for patients who have little to no treatment options. PTC’s strategy is to leverage its strong scientific and clinical expertise and global commercial infrastructure to bring therapies to patients. PTC believes this allows it to maximize value for all its stakeholders. To learn more about PTC, please visit us at www.ptcbio.com and follow us on Facebook, on Twitter at @PTCBio, Instagram and on LinkedIn.
For More Information:
Jeanine Clemente
jclemente@ptcbio.com
View original content:https://www.prnewswire.com/apac/news-releases/australian-patient-advocacy-organization-named-a-recipient-of-ptc-therapeutics-2023-strive-award-for-duchenne-muscular-dystrophy-301919793.html
SOURCE PTC Therapeutics, Inc.
